CZ172497A3 - Fragments of monoclonal substance exhibiting immunosuppressor activity - Google Patents

Fragments of monoclonal substance exhibiting immunosuppressor activity Download PDF

Info

Publication number
CZ172497A3
CZ172497A3 CZ971724A CZ172497A CZ172497A3 CZ 172497 A3 CZ172497 A3 CZ 172497A3 CZ 971724 A CZ971724 A CZ 971724A CZ 172497 A CZ172497 A CZ 172497A CZ 172497 A3 CZ172497 A3 CZ 172497A3
Authority
CZ
Czechia
Prior art keywords
rule
fab fragment
substitute sheet
mab
fab
Prior art date
Application number
CZ971724A
Other languages
Czech (cs)
English (en)
Inventor
Zoltan Nagy
Damir Vidovic
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CZ172497A3 publication Critical patent/CZ172497A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CZ971724A 1994-12-07 1995-11-25 Fragments of monoclonal substance exhibiting immunosuppressor activity CZ172497A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35091594A 1994-12-07 1994-12-07
PCT/EP1995/004648 WO1996017874A1 (fr) 1994-12-07 1995-11-25 Fragments d'anticorps monoclonaux possedant une activite immunodepressive

Publications (1)

Publication Number Publication Date
CZ172497A3 true CZ172497A3 (en) 1997-10-15

Family

ID=23378740

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ971724A CZ172497A3 (en) 1994-12-07 1995-11-25 Fragments of monoclonal substance exhibiting immunosuppressor activity

Country Status (19)

Country Link
EP (1) EP0787151A1 (fr)
JP (1) JP2001506122A (fr)
CN (1) CN1168679A (fr)
AR (1) AR002005A1 (fr)
AU (1) AU4256096A (fr)
BR (1) BR9509902A (fr)
CA (1) CA2206471A1 (fr)
CO (1) CO4480041A1 (fr)
CZ (1) CZ172497A3 (fr)
FI (1) FI972430A0 (fr)
HU (1) HUT77342A (fr)
IL (1) IL116228A0 (fr)
MA (1) MA23739A1 (fr)
NO (1) NO972522L (fr)
PE (1) PE52996A1 (fr)
PL (1) PL320610A1 (fr)
TR (1) TR199501542A2 (fr)
WO (1) WO1996017874A1 (fr)
ZA (1) ZA9510195B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0893507A1 (fr) * 1997-07-25 1999-01-27 Institut Gustave Roussy Utilisation de ligands de MHC classe II (CD4 et LAG-3) comme adjuvants pour la vaccination de LAG-3 dans le traitement du cancer
WO2000012560A1 (fr) * 1998-08-28 2000-03-09 Dendreon Corporation Apoptose selective de cellules neoplasiques mise en oeuvre par un anticorps monoclonal specifique au hla-dr
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
EP1156062A1 (fr) * 2000-05-12 2001-11-21 GPC Biotech AG Peptides/protéines immunomodulants et liants à un antigène du CMH classe II humain
EP1156060B1 (fr) * 2000-05-12 2007-06-27 GPC Biotech AG Peptides/protéines humaines causant ou menant à la mort de cellules y compris de cellules lymphoides tumorales
US20030082188A1 (en) 2001-10-11 2003-05-01 Tso J. Yun Treatment of prostate cancer by inhibitors of NCAM2
CN1571797A (zh) 2001-10-15 2005-01-26 麒麟麦酒株式会社 抗hla－dr抗体
WO2006115509A2 (fr) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
CA2794499A1 (fr) * 2010-04-01 2011-10-06 Immumomedics, Inc. Utilisation d'anticorps pour reduire le nombre de cellules contenant des antigenes et de cellules dendritiques
KR102647825B1 (ko) * 2021-07-22 2024-03-14 서울대학교산학협력단 항-hla-dp 단클론 항체 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3269354D1 (en) * 1981-06-25 1986-04-03 Univ Leland Stanford Junior Allele specific immunotherapeutic method and dosage form
DE69028713T3 (de) * 1989-12-27 2004-05-13 Centocor, Inc. Schimäre immunoglobuline für cd4-rezeptoren
ATE327331T1 (de) * 1991-07-25 2006-06-15 Biogen Idec Inc Rekombinante antikörper zur humanen therapie

Also Published As

Publication number Publication date
EP0787151A1 (fr) 1997-08-06
CN1168679A (zh) 1997-12-24
FI972430A7 (fi) 1997-06-06
NO972522L (no) 1997-08-06
AU4256096A (en) 1996-06-26
BR9509902A (pt) 1997-10-21
PL320610A1 (en) 1997-10-13
AR002005A1 (es) 1998-01-07
MA23739A1 (fr) 1996-07-01
PE52996A1 (es) 1996-12-12
TR199501542A2 (tr) 1996-07-21
MX9704225A (es) 1997-09-30
NO972522D0 (no) 1997-06-03
HUT77342A (hu) 1998-03-30
CO4480041A1 (es) 1997-07-09
FI972430L (fi) 1997-06-06
ZA9510195B (en) 1996-06-07
WO1996017874A1 (fr) 1996-06-13
FI972430A0 (fi) 1997-06-06
JP2001506122A (ja) 2001-05-15
IL116228A0 (en) 1996-03-31
CA2206471A1 (fr) 1996-06-13

Similar Documents

Publication Publication Date Title
AU2019200159B2 (en) CD-3 binding molecules capable of binding to human and non-human CD3
US5885573A (en) Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US7034121B2 (en) Antibodies against CTLA4
US6491916B1 (en) Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
Alegre et al. An anti-murine CD3 monoclonal antibody with a low affinity for Fc γ receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity
RU2203682C2 (ru) Фармацевтическая композиция для лечения иммунных заболеваний
JP7384835B2 (ja) Ｃｄ３に特異的な抗体及びその使用
US20060002933A1 (en) Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
WO1994028027A9 (fr) Procedes et matieres de modulation de l'activite immunodepressive et de la toxicite d'anticorps monoclonaux
KR19990022650A (ko) 사람 ｂ7.1 및/또는 ｂ7.2 영장류화된 형태에 특이적인 원숭이 단일클론성 항체 및 이의 약제학적 조성물
HUP9904697A2 (hu) Eljárások és készítmények immunmodulációhoz
Kostelny et al. Humanization and characterization of the anti‐HLA‐DR antibody 1D10
US7501264B2 (en) Methods of producing 7C10 and 16C10 CD80-specific antibodies
JP2002540764A (ja) Ｂ７分子と反応するヒト化免疫グロブリンおよびそれを用いた治療方法
WO1996017874A1 (fr) Fragments d'anticorps monoclonaux possedant une activite immunodepressive
JPH07242566A (ja) 免疫抑制剤
US20030161827A1 (en) Therapies that improve graft survival
MXPA97004225A (en) Fragments of monoclonal antibodies that have immunosuppressive activity
CN121487961A (zh) 抗kras/hla抗体及其用途
Zhang Three antibody-based immunotherapeutic modalities for malignancies
JP2004261182A (ja) 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
MXPA99004296A (en) Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens